The drug can cross the blood-brain barrier (BBB) and activate GLP-1R in the CNS [49, 50], thus producing neuroprotective and anti-inflammatory effects [50,51,52,53,54,55]
Our earlier studies showed that IL-6 induces proteasomal degradation of DNMT1 and induces DNA methylation-dependent gene expression related to insulin signalling and angiogenesis [43]
Considering the chronic nature of diabetes-related complications (e.g., CVDs), the follow-up period of this real-world study may not be sufficient to assess the long-term benefits of GLP-1RA therapy
Trulicity offers FDA-approved cardiovascular risk reduction and is approved for pediatric patients aged 10 and older
The GIP receptor activation in tirzepatide may actually moderate some GLP-1-related GI effects, and many users report that tirzepatide is slightly better tolerated gastrointestinally than semaglutide despite being more effective
To view or add a comment, sign in The FDA announced nine voucher recipients under the new Commissioners National Priority Voucher (CNPV) pilot program
